Newmanbrain
Newmanbrain develops portable neuroimaging systems and associated software to support objective assessment of cognitive conditions. The company combines functional near-infrared spectroscopy (fNIRS) hardware, cloud-based analytics and machine learning to generate rapid cognitive-assessment reports intended for clinical screening, longitudinal monitoring and research applications. Newmanbrain has presented its technology at multiple industry events and reports awarded design recognition and a granted patent.
Industries
Nr. of Employees
small (1-50)
Newmanbrain
Alicante, Comunidad Valenciana, Spain, Europe
Patents
Products
Theia — fNIRS portable neuroimaging device
Portable fNIRS-based device combined with software for capturing prefrontal hemodynamic signals, transmitting data to cloud analytics and producing cognitive-assessment reports for MCI and related conditions.
Theia — fNIRS portable neuroimaging device
Portable fNIRS-based device combined with software for capturing prefrontal hemodynamic signals, transmitting data to cloud analytics and producing cognitive-assessment reports for MCI and related conditions.
Services
Cloud-based assessment service that ingests fNIRS data, runs machine learning models and returns a probability-based cognitive assessment report in near real time.
Cloud-based assessment service that ingests fNIRS data, runs machine learning models and returns a probability-based cognitive assessment report in near real time.
Expertise Areas
- Neuroimaging using fNIRS
- AI-driven cognitive assessment
- Portable medical device design
- Clinical data collection and validation
Key Technologies
- Functional near-infrared spectroscopy (fNIRS)
- Supervised machine learning / AI classification
- Cloud analytics and reporting
- Real-time data visualization
News & Updates
Company CEO attended the JP Morgan Healthcare Conference to engage with investors and industry leaders.
Unveiled AI-powered fNIRS technology for MCI detection and demonstrated cloud-based assessment workflow.
Showcased portable neurotechnology and pursued US market partnerships and investor engagement.
Regular participation in NeurotechEU summit, Longevity World Forum, Iberian and regional healthcare events to present technology and research.
Company and its fNIRS device were pre-selected within the Insud Pharma ChemoStart program to receive mentorship and support.
Article describes the portable fNIRS system, AI analytics and reported testing on over 600 people.
Company CEO attended the JP Morgan Healthcare Conference to engage with investors and industry leaders.
Unveiled AI-powered fNIRS technology for MCI detection and demonstrated cloud-based assessment workflow.
Showcased portable neurotechnology and pursued US market partnerships and investor engagement.
Regular participation in NeurotechEU summit, Longevity World Forum, Iberian and regional healthcare events to present technology and research.
Company and its fNIRS device were pre-selected within the Insud Pharma ChemoStart program to receive mentorship and support.
Article describes the portable fNIRS system, AI analytics and reported testing on over 600 people.